Fluad Quadrivalent (inactivated quadrivalent influenza vaccine) / CSL Behring - LARVOL DELTA

Meta-analysis of Relative Vaccine Effectiveness of Adjuvanted (aTIV/aQIV) vs High-dose Influenza Vaccines (HD-TIV/HD-QIV) for Prevention of Influenza (IDWeek 2026) - No abstract available

Retrospective data • Infectious Disease • Influenza

Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial. (PubMed, Lancet Infect Dis) - P3 | "In adults aged 50 years or older, aQIVc was non-inferior and superior to aQIV for all four influenza strains and non-inferiority criteria for aQIVc versus QIVr were met for A/H1N1 and both B strains, but not A/H3N2. No safety concerns were identified."

Journal • P3 data • Infectious Disease • Influenza • Respiratory Diseases

Adjuvanted and high-dose influenza vaccines had comparable effectiveness against test-confirmed influenza outcomes including hospitalizations in overall and high-risk older adults in the 2022-2023 and 2023-2024 seasons. (PubMed, Int J Infect Dis) - "aQIV and HD-QIV provided comparable protection for prevention of test-confirmed influenza among older adults in any and ED/hospitalization settings in the 2023-2024 season and for hospitalizations in overall and high-risk older adults in pooled 2022-2024 analyses."

Journal • Infectious Disease • Influenza • Respiratory Diseases

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (clinicaltrials.gov) - P3 | N=38769 | Completed | Sponsor: Seqirus | Active, not recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Jun 2026 | Trial primary completion date: Nov 2026 ➔ May 2026

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial. (PubMed, J Infect) - "COVID-19 vaccine and aQIV can be safely co-administered with both doses of RZV without impacting the immunogenicity of any of the vaccines."

Journal • Herpes Zoster • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases • Varicella Zoster

Potential to Avert Additional Influenza Burden in the United States with Use of Adjuvanted vs. Standard Influenza Vaccines in Individuals 50-64 Years of Age. (PubMed, Vaccines (Basel)) - "Individuals aged 50-64 years could benefit from use of aTIV/aQIV over TIV/QIV, with an average increase in the number of influenza outcomes prevented of 15.2% per 5% improvement in vaccine effectiveness."

Journal • Critical care • Infectious Disease • Influenza • Respiratory Diseases

EDUCATE: Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP (clinicaltrials.gov) - P3 | N=192 | Completed | Sponsor: Centers for Disease Control and Prevention | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

VON TRAPP: Vaccination Response Modulation With a Targeted Rapamycin Protocol Study (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Central Adelaide Local Health Network Incorporated

New P2 trial • CXCL8

Cost-effectiveness of vaccination of older adults with an MF59®-adjuvanted quadrivalent influenza vaccine compared to standard-dose and high-dose vaccines in South Korea and Taiwan. (PubMed, Vaccine) - "Our results imply that introducing aQIV for the ≥65 population might significantly reduce the clinical and economic burden of influenza in these countries. These findings support the benefits of aQIV as an enhanced influenza vaccine in national immunization programs targeting ≥65 year olds."

HEOR • Journal • Infectious Disease • Influenza • Respiratory Diseases

Increased anti-N2 neuraminidase immune responses with MF59-adjuvanted aQIVc vs aQIV and QIVr and implications for A/H3N2 protection in older adults (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease • Influenza • Respiratory Diseases

mRNA-CRID-001: A Study of Modified mRNA Vaccines in Healthy Adults (clinicaltrials.gov) - P1 | N=308 | Completed | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Completed

Trial completion • Cytomegalovirus Infection • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Early lymph node T follicular helper cell signalling hub drives influenza vaccine response in an ancestrally diverse cohort. (PubMed, EBioMedicine) - "Early CD4+ Tfh coordination in draining lymphoid tissue underpins robust responses to adjuvanted influenza vaccine that transcend ancestral inter-individual variation in young adults, with implications for vaccine design in ancestrally-diverse populations."

Journal • Infectious Disease • Influenza • Respiratory Diseases • CD4

Brand-specific influenza vaccine effectiveness in three Nordic countries during the 2024-2025 season: a target trial emulation study based on registry data. (PubMed, Lancet Reg Health Eur) - "Brand-specific VE was 63.4% (38.1-88.7) for Efluelda Tetra (split virion-high dose), 48.2% (40.8-55.6) for Fluad Tetra (subunit standard-dose adjuvanted), 43.6% (23.7-63.6) for Vaxigrip Tetra (split virion standard-dose), and 30.6% (-7.8 to 69.1) for Influvac Tetra (subunit standard-dose)...Annual monitoring using Nordic registries is crucial for informing evidence-based vaccination strategies and regulatory decisions. European Medicines Agency."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Influenza Vaccination Appropriateness: Insights from the Local Health Unit of Catania During the 2023/2024 and 2024/2025 Seasons. (PubMed, Vaccines (Basel)) - "All other groups maintained high adherence (≥99%), except for 6.2% of children aged 6 months-2 years who inappropriately received LAIV. Despite dramatically improved vaccination appropriateness in the elderly, a persistent and critical safety issue--inappropriate administration LAIV use in 6.2% of young children-highlights the need for targeted interventions to ensure complete patient safety."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Health Technology Assessment del vaccino antinfluenzale quadrivalente adiuvato Fluad Tetra®: update. (PubMed, J Prev Med Hyg) - No abstract available

Journal • Infectious Disease • Respiratory Diseases

Comparable Effectiveness of MF59®-Adjuvanted and High-Dose Quadrivalent Inactivated Influenza Vaccines for Prevention of Test-Confirmed Influenza During the 2022-2023 Influenza Season. (PubMed, Int J Infect Dis) - "Similar to previous studies, aQIV and HD-QIV provided comparable protection against test-confirmed influenza in any setting, including ED/inpatient, aligning with ACIP and other recommendations for adults ≥65 years."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Muscle macrophage regenerative response after squalene-adjuvanted influenza vaccination drives Th2-skewed response and is reduced with age (IMMUNOLOGY 2025) - "The yBMDMs infiltrated the muscle, internalized the vaccine, and drained to the lymph nodes, rescuing the Th2 response in the lungs. Our findings highlight the role of macrophages in vaccine response and underscore the importance of studying muscle regeneration and factors affecting it like age when developing vaccines.Keywords: Animals Rodent; Cells Monocytes/Macrophages Th1/Th2 Cells; Infections Viral; Processes Antigen Presentation/Processing"

Clinical • Infectious Disease • Influenza • Respiratory Diseases • CD8 • CX3CR1

Cost-Effectiveness of Adjuvanted Influenza Vaccine Compared with Standard and High-Dose Influenza Vaccines for Persons Aged ≥50 Years in Spain. (PubMed, Vaccines (Basel)) - "In the model, aQIV dominated QIVe and HD-QIV, demonstrating that aQIV use would be cost-saving for persons aged ≥50 years who are at high risk of influenza complications."

HEOR • Journal • Infectious Disease • Influenza • Respiratory Diseases

Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection (clinicaltrials.gov) - P=N/A | N=1500 | Active, not recruiting | Sponsor: University of Melbourne | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2023 ➔ Jun 2025 | Trial primary completion date: Nov 2023 ➔ Jun 2025

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older. (PubMed, Vaccine) - P2 | "These data support further investigation of additional formulations of aQIVc in adults aged ≥50 years. Clinical trial registry:NCT04576702."

Journal • P2 data • Infectious Disease • Influenza • Respiratory Diseases

Immunogenicity and safety of the MF59-adjuvanted seasonal influenza vaccine in non-elderly adults: A systematic review and meta-analysis. (PubMed, PLoS One) - "In non-elderly adults, aTIV/aQIV is safe and generally more immunogenic than non-adjuvanted standard-dose vaccines."

Journal • Retrospective data • Infectious Disease • Influenza • Respiratory Diseases

Relative Vaccine Effectiveness of Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aQIV) vs High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-QIV) Against Test-Confirmed Influenza During the 2022-2023 Influenza Season (ISIRV-OPTIONS XII 2024) - No abstract available

Clinical • Infectious Disease • Influenza • Respiratory Diseases

Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial. (PubMed, Clin Infect Dis) - P3 | "Adjuvanted FLU-aQIV and RSVPreF3 OA had acceptable reactogenicity/safety profiles when co-administered in ≥65-year-olds, without clinically relevant interference with the immune responses to either vaccine."

Journal • P3 data • Infectious Disease • Influenza • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (clinicaltrials.gov) - P3 | N=35800 | Recruiting | Sponsor: Seqirus | Active, not recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Influenza • Respiratory Diseases

Cost-Effectiveness of Adjuvanted Quadrivalent Influenza Vaccine for Adults over 65 in France. (PubMed, Vaccines (Basel)) - "This study highlights the cost-effectiveness of aQIV versus SD-QIV and HD-QIV, preventing influenza cases, hospitalizations, and deaths."

Cost effectiveness • HEOR • Journal • Infectious Disease • Influenza • Respiratory Diseases